Founding offer · lifetime membership for a single £24, exclusive to our first members · closes 20 June Claim your place →
Global Research Partnerships £24 Lifetime Log inCreate free account

Funded Projects › HORIZON

Yellow4FLAVI · Deconstructing the protective immunity of yellow fever virus 17D to inform flavivirus vaccine design

HORIZONStatus: SIGNED1 January 202431 December 2028EU funding €8,544,781Call HORIZON-HLTH-2023-DISEASE-03

While endemic to the tropics, flaviviruses like Zika, dengue, West Nile or yellow fever virus are re-emerging pathogens of global health concern. Climate change and urbanization have largely contributed to the dissemination of their mosquito vector and Europe has in recent years been regularly confronted with autochthonous cases. Few vaccines are licensed to prevent flavivirus disease, but the yellow fever 17D (YF17D) vaccine has a unique track record of efficiency and safety. Intriguingly, despite its success, how YF17D induces immunity remains poorly understood. The YELLOW4FLAVI consortium aims to fill the gaps in our understanding of the mechanism of action of this vaccine by linking the structure of the viral particle to the resulting host immune response, in order to learn about optimal vaccine design for flaviviruses in general. Since social acceptance of vaccines is critical for their success, we will also develop optimal communication methods. This will provide us with the tools to tailor vaccine design not only to achieve optimal immune protection, but also to facilitate actual implementation.We are molecular and structural virologists, cell biologists, immunologists, computational scientists, clinicians, and social scientists assembled in a tight collaborative network. To pursue our goal of obtaining a blueprint for determinants of long-lasting immunity for flavivirus vaccine candidates, we will use cutting-edge technologies like cryo-EM, super resolution microscopy, spatial transcriptomics, high-dimensional spectral flow cytometry, single-cell RNA sequencing, advanced cell engineering, small animal models, and clinical studies. In a unique manner, the consortium thereby follows a thread of events from the early response at the site of vaccine injection to the population perception of vaccination, harnessing an enhanced understanding of one of the most successful vaccines of mankind for the development of novel lines of defense against new and old threats.

Consortium · 14 organisations

coordinator

INSTITUT PASTEUR

FR · €1,744,925

participant

LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN

DE · €1,997,048

participant

STICHTING AMSTERDAM INSTITUTE FOR GLOBAL HEALTH AND DEVELOPMENT

NL · €151,255

participant

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE

FR · €278,375

participant

CORPORACION CENTRO INTERNACIONAL DE ENTRENAMIENTO E INVESTIGACIONES MEDICAS

CO · €697,239

thirdParty

KLINIKUM DER LUDWIG-MAXIMILIANS-UNIVERSITAT MUNCHEN

DE

participant

UNIVERSITA DEGLI STUDI DI PADOVA

IT · €294,291

participant

CHARITE - UNIVERSITAETSMEDIZIN BERLIN

DE · €601,828

participant

ISTITUTO ZOOPROFILATTICO SPERIMENTALE DELL'ABRUZZO E DEL MOLISE G CAPORALE

IT · €360,156

participant

OMNISCOPE LIMITED

MT · €534,015

participant

IMMUNEWATCH BV

BE · €328,733

participant

UNIVERSITATSKLINIKUM ERLANGEN

DE · €727,350

participant

KATHOLIEKE UNIVERSITEIT LEUVEN

BE · €370,325

participant

TURUN YLIOPISTO

FI · €459,241

Research fields

View the official record on CORDIS →

← Find collaborators and more funded projects

Source: CORDIS, Publications Office of the European Union. Global Research Partnerships surfaces open EU research data to help you find collaborators; we are not affiliated with the European Union.